Diabetes Canada 2020 Pharmacotherapy Chapter Update (Diabetes Simplified - Practical Recommendations to Improve Diabetes Care)
The Diabetes Canada pharmacotherapy in type 2 diabetes guideline chapter was recently updated. After completing this module, primary care clinicians should be able to interpret the latest guideline evidence, apply them to clinical cases and be more comfortable integrating the new recommendations into their practices.
This program is developed in collaboration with Partners in Progressive Medical Education (PPME), and endorsed by Diabetes Canada.
This program has received an educational grant or in-kind support from Abbott Diabetes Care, Astra Zeneca, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc., Janssen, Novo Nordisk and Sanofi.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits. Cert+ Program ID#: 193524
Peter Senior, MBBD, PhD, FRCP
James Kim, MBBCh, PgDip
Maureen Clement, MD, CCFP
Peter J. Lin, MD, CCFP
- Review the key changes in the Diabetes Canada 2020 pharmacotherapy in type 2 diabetes chapter of the guidelines
- Determine the patient and agent factors that should be considered when initiating antihyperglycemic pharmacotherapy in type 2 diabetes
- Discuss how primary care clinicians can integrate these recommendations for managing patients with type 2 diabetes in their practices